8-K: Galectin Therapeutics Provides Business Update and Reports Q2 2024 Financial Results

Galectin Therapeutics announced its Q2 2024 financial results and provided a business update, highlighting the progress of its NAVIGATE trial and upcoming interim analysis.

Summary

• Galectin Therapeutics reported its financial results for the quarter ended June 30, 2024, and provided an update on its business activities.
• The company's NAVIGATE Phase 2b/3 trial of belapectin for MASH-related cirrhosis is progressing as planned, with an interim top-line data readout expected in December 2024.
• Research and development expenses increased to $9.8 million in Q2 2024, compared to $7.4 million in Q2 2023, primarily due to the timing of expenditures related to the NAVIGATE trial.
• The company's net loss for Q2 2024 was $12.4 million, or ($0.20) per share, compared to a net loss of $9.2 million, or ($0.15) per share, for the same period in 2023.
• As of June 30, 2024, Galectin Therapeutics had $25.6 million in cash and cash equivalents, and an additional $10 million available under a line of credit.
• The company believes it has sufficient cash to fund operations through approximately May 15, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the clinical trial is progressing as planned, the increased net loss and R&D expenses are concerning. The company's cash runway is also a key factor to monitor.

Positives

• The NAVIGATE trial is progressing as planned, indicating the company is on track with its clinical development timeline.
• The company has sufficient cash to fund operations through approximately May 15, 2025.
• The company presented data at the EASL 2024 congress, highlighting the importance of endoscopies in assessing esophageal varices.

Negatives

• The company experienced a net loss of $12.4 million in Q2 2024, which is an increase from the $9.2 million loss in Q2 2023.
• Research and development expenses increased significantly, primarily due to the NAVIGATE trial.

Risks

• The company's future financial performance could differ significantly from management's expectations.
• The success of the belapectin program is subject to risks and uncertainties, including the possibility that trial endpoints may not be achieved.
• The company may not be successful in developing effective treatments or obtaining the necessary approvals.
• The company may not be successful in scaling up manufacturing or meeting regulatory requirements.
• The company's clinical trials may not produce positive results, and may require larger and longer trials.
• The company may be unsuccessful in developing partnerships or raising additional capital.

Future Outlook

The company anticipates an interim top-line data readout from the Phase 2b portion of the NAVIGATE trial in December 2024 and believes it has sufficient cash to fund operations through approximately May 15, 2025.

Management Comments

• Joel Lewis, CEO, stated that they continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024.
• Joel Lewis believes that belapectin can potentially offer a new medical treatment option for patients with MASH associated liver cirrhosis and portal hypertension.
• Khurram Jamil, CMO, highlighted data from the belapectin program demonstrating that collagen content in liver biopsies does not correlate with portal pressure.

Industry Context

Galectin Therapeutics is focused on developing therapies for chronic liver disease and cancer, specifically targeting galectin-3. The company's lead program is in MASH with cirrhosis, a significant unmet medical need. The company is also exploring other indications such as cancer immunotherapy.

Comparison to Industry Standards

• Galectin Therapeutics is developing belapectin, a galectin-3 inhibitor, for MASH-related cirrhosis, a space with significant unmet need and competition from companies like Intercept Pharmaceuticals (obeticholic acid) and Madrigal Pharmaceuticals (resmetirom).
• The NAVIGATE trial is a Phase 2b/3 trial, which is a common approach for companies in this space, but the interim analysis in December 2024 will be a key milestone to compare against other companies' timelines.
• The company's cash position of $25.6 million, plus $10 million available credit, is relatively low compared to larger pharmaceutical companies, but is typical for a clinical-stage biotech company. The cash runway to May 2025 is a key metric to watch.
• The increase in R&D expenses to $9.8 million is expected for a company advancing a Phase 2b/3 trial, but the net loss of $12.4 million is a concern and will need to be monitored against industry benchmarks.

Stakeholder Impact

• Shareholders will be impacted by the increased net loss and the progress of the NAVIGATE trial.
• Employees are likely to be impacted by the company's financial performance and the progress of its clinical programs.
• Patients with MASH-related cirrhosis may benefit from the development of belapectin if the clinical trials are successful.

Next Steps

• The company will continue to advance the NAVIGATE Phase 2b/3 trial of belapectin.
• The company anticipates an interim top-line data readout from the Phase 2b portion of the NAVIGATE trial in December 2024.
• The company will continue to seek partnerships for its other development programs.

Key Dates

Keywords

Galectin Therapeutics, belapectin, MASH, cirrhosis, NAVIGATE trial, clinical trial, financial results, research and development, net loss, cash equivalents, galectin-3, esophageal varices, portal hypertension